公开(公告)号：US20220143069A1

公开(公告)日：2022-05-12

申请号：US17593391

申请日：2020-04-01

Applicant: BIONTECH SE

Inventor： Heinrich HAAS ,  Sebastian HÖRNER ,  Thomas Michael HILLER

IPC: A61K31/7105 ,  A61K47/18 ,  A61K47/02 ,  A61K47/26 ,  A61K47/22

Abstract: The present disclosure relates to methods for preparing RNA lipoplex particles for delivery of RNA to target tissues after parenteral administration, in particular after intravenous administration, and compositions comprising such RNA lipoplex particles. The present disclosure also relates to methods which allow preparing RNA lipoplex particles in an industrial GMP-compliant manner. Furthermore, the present disclosure relates to methods and compositions for storing RNA lipoplex particles without substantial loss of the product quality and, in particular, without substantial loss of RNA activity.

公开(公告)号：US20220064317A1

公开(公告)日：2022-03-03

申请号：US17360437

申请日：2021-06-28

Applicant: GENMAB A/S ,  BioNTech SE

Inventor： Isil ALTINTAS ,  David SATIJN ,  Rik RADEMAKER ,  Paul PARREN ,  Friederike GIESEKE ,  Ugur SAHIN

IPC: C07K16/28 ,  A61K39/395 ,  G01N33/569

Abstract: Multispecific antibodies binding to human CD40 and human CD137, methods for preparing such multispecific antibodies, and methods of using such multispecific antibodies for therapeutic or other purposes.

公开(公告)号：US11222711B2

公开(公告)日：2022-01-11

申请号：US14787110

申请日：2014-05-07

Applicant: BioNTech SE ,  TRON—TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG—UNIVERSITAT MAINZ GEMEINNUTZIGE GMBH

Inventor： Ugur Sahin ,  Arbel David Tadmor ,  John Christopher Castle ,  Sebastian Boegel ,  Martin Löwer

IPC: G16B20/20 ,  G16B20/00 ,  A61K39/00 ,  C12Q1/6886

Abstract: The present invention relates to methods for predicting T cell epitopes. In particular, the present invention relates to methods for predicting whether modifications in peptides or polypeptides such as tumor-associated neoantigens are immunogenic or not. The methods of the invention are useful, in particular, for the provision of vaccines which are specific for a patient's tumor and, thus, in the context of personalized cancer vaccines.

公开(公告)号：US11091557B2

公开(公告)日：2021-08-17

申请号：US16316534

申请日：2017-07-14

Applicant: GENMAB A/S ,  BioNTech SE

Inventor： Isil Altintas ,  David Satijn ,  Rik Rademaker ,  Paul Parren ,  Friederike Gieseke ,  Ugur Sahin

IPC: A61K39/395 ,  C07K16/28 ,  G01N33/569

Abstract: Multispecific antibodies binding to human CD40 and human CD137, methods for preparing such multispecific antibodies, and methods of using such multispecific antibodies for therapeutic or other purposes.

公开(公告)号：US10927181B2

公开(公告)日：2021-02-23

申请号：US16582534

申请日：2019-09-25

Applicant: BIONTECH SE ,  GENMAB A/S

Inventor： Ugur Sahin ,  Friederike Gieseke ,  Isil Altintas ,  David Satijn ,  Paul Parren

IPC: C07K16/28

Abstract: The present invention relates to binding agents binding to receptors of the TNF superfamily, in particular binding agents binding to at least two different receptors of the TNF superfamily, as well as to their use in medicine. The present invention further relates to nucleic acid molecules encoding such binding agents, to cells comprising such nucleic acid molecules and to pharmaceutical compositions and kits.

公开(公告)号：US20210002249A1

公开(公告)日：2021-01-07

申请号：US16644079

申请日：2018-08-31

Applicant: BIONTECH SE

Inventor： Christophe HENRY

IPC: C07D401/04 ,  A61P35/00

Abstract: The invention relates to imidazoquinoline derivatives and to pharmaceutical compositions containing the imidazoquinoline derivatives. The imidazoquinoline derivatives of the invention are useful as toll-like receptor agonists, in particular agonists of TLR7, and promote induction of certain cytokines.

公开(公告)号：US12281322B2

公开(公告)日：2025-04-22

申请号：US17494601

申请日：2021-10-05

Applicant: BIONTECH SE ,  TRON-Translationale Onkologie an der Universitätsmedizin der Johanne Gutenberg-Universität Mainz gem

Inventor： Tim Beissert ,  Ugur Sahin ,  Mario Perkovic

IPC: C12N15/86

Abstract: The present invention embraces a RNA replicon that can be replicated by a replicase of alphavirus origin. The RNA replicon comprises sequence elements required for replication by the replicase, but these sequence elements do not encode any protein or fragment thereof, such as an alphavirus non-structural protein or fragment thereof. Thus, in the RNA replicon according to the invention, sequence elements required for replication by the replicase and protein-coding region(s) are uncoupled. According to the present invention the uncoupling is achieved by the removal of at least one initiation codon compared to a native alphavirus genomic RNA. In particular, the RNA replicon comprises a 5′ replication recognition sequence, wherein the 5′ replication recognition sequence is characterized in that it comprises the removal of at least one initiation codon compared to a native alphavirus 5′ replication recognition sequence. The replicase of alphavirus origin may be encoded by an open reading frame on the RNA replicon or on a separate RNA molecule. The present invention enables efficient and safe expression of a protein of interest in a cell or organism, but is not associated with undesired production of fragments of alphavirus non-structural protein. Methods of protein production in vitro and in vivo, as well as medical uses, are provided herein.

公开(公告)号：US20250057960A1

公开(公告)日：2025-02-20

申请号：US18702858

申请日：2022-10-21

Applicant: BioNTech SE ,  Consejo Superior de Investigaciones Científicas (CSIC) ,  Universidad de Sevilla

Inventor： Jorge Moreno Herrero ,  Heinrich Haas ,  Stephanie Erbar ,  Theo Benjamin Stahl ,  José Manuel García Fernández ,  Juan Manuel Benito Hernández ,  Jose Lopez Fernandez ,  Maria del Carmen Ortiz Mellet ,  Noelia de la Cruz Ruiz ,  Manuel González Cuesta ,  Egon Jack Jacobus Ambuludi ,  Irena Vlatkovic

IPC: A61K47/54 ,  A61K9/00 ,  A61K31/713 ,  A61P31/16 ,  C12N15/88

Abstract: The present disclosure provides complexes comprising: i) a cationic oligosaccharide comprising one or more cationic moieties bonded to a trehalose, a sucrose, or a gluco-n-oligosaccharide moiety, where n is 2-6; ii) a surfactant; and iii) one or more additives selected from: a sterol, a helper lipid, an immunomodulator, and a targeting molecule; and uses thereof.

公开(公告)号：US20250009780A1

公开(公告)日：2025-01-09

申请号：US18578844

申请日：2022-07-13

Applicant: BIONTECH SE

Inventor： Ugur SAHIN ,  Christiane STADLER ,  Claudia LINDEMANN ,  Ursula ELLINGHAUS ,  Hayat BÄHR-MAHMUD ,  Leyla FISCHER ,  Anuhar CHATURVEDI ,  Gábor BOROS ,  Jonas REINHOLZ ,  Sergey BESSONOV ,  Katalin KARIKÓ

IPC: A61K31/7115 ,  A61K9/00 ,  A61K9/127 ,  A61K9/51 ,  A61K45/06 ,  A61P35/00 ,  C07K16/28

Abstract: The present invention generally relates to binding agents that are at least bispecific for the binding to CD3 and CLDN6, i.e., they are capable of binding to at least CD3 and CLDN6. Specifically, the present invention relates to RNA encoding these binding agents which may be used in the treatment or prevention of cancer in a subject.

公开(公告)号：US20250002600A1

公开(公告)日：2025-01-02

申请号：US18696689

申请日：2022-10-05

Applicant: Genmab A/S ,  BioNTech SE

Inventor： Alexander MUIK ,  Kristina SCHÖDEL ,  Nora PENCHEVA ,  Maria N. JURE-KUNKEL ,  Ugur SAHIN ,  Sina FELLERMEIER-KOPF ,  Patricia GARRIDO CASTRO ,  Jordan BLUM ,  Friederike GIESEKE ,  Esther C. W. BREIJ ,  Lars GUELEN ,  Joost NEIJSSEN ,  Karsten BECKMANN ,  Claudia PAULMANN ,  Bart-Jan DE KREUK ,  Richard G. HIBBERT ,  Janine SCHUURMAN ,  Aran LABRIJN ,  Ivan KUZMANOV

IPC: C07K16/28 ,  A61K9/00 ,  A61K39/00 ,  A61P35/00

Abstract: The present invention provides combination therapy using a binding agent that binds to human CD137 and to human PD-L1 in combination with a PD-1 inhibitor to reduce or prevent progression of a tumor or treating cancer.